Diabetes, COPD Raise Post-Kidney Transplant Readmission Rates High phosphate levels are associated with 3.3-fold increased odds of 28-day in-hospital mortality. Hyperphosphatemia predicts an increased ...

Tenapanor, a novel agent that has been submitted to the US Food and Drug Administration (FDA) for approval for the treatment of hyperphosphatemia in patients undergoing dialysis, moved a step closer ...

Given the suboptimal outcomes with existing therapies to manage chronic kidney disease patients on dialysis, there is a substantial unmet need that additional treatment options could potentially ...

As a physician and researcher caring for people with chronic kidney disease, I see firsthand the challenges that patients undergoing dialysis face. Dialysis is life-sustaining, but it also brings ...

A research team from Argentina prospectively studied the frequency of hyperphosphatemia following the administration of oral sodium phosphate (OSP) in low-risk patients. They found that the standard ...

Investigators ruled out hyperphosphatemia and SHPT as confounders in each other's association with CKD outcomes. Secondary hyperparathyroidism (SHPT) is associated with progression of chronic kidney ...

Please provide your email address to receive an email when new articles are posted on . Phase 3 results from the PHREEDOM study demonstrated treatment with tenapanor safely and effectively decreased ...

Chewing gum made with a phosphate-binding ingredient can help treat high phosphate levels in dialysis patients with chronic kidney disease, according to a new study. The results suggest that this ...

Credit: Ardelyx. Xphozah is a first-in-class oral medication designed to block sodium/hydrogen exchange 3 in the GI tract. Xphozah ® (tenapanor) is now available to reduce serum phosphorus in adults ...